Intelligent Investor

Immuron Limited (ASX: IMC) - Share Price and Research

- Current share price for IMC : $0.100

Immuron Limited (IMC), an ASX-listed company, is commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies in the treatment of diseases with associated with the gastrointestinal tract. The group is involved in Research & Development and Hyperimmune Products (occur predominantly in Australia, the Unites States and Canada).

IMC General Information +

ASX Code IMC
Website http://www.immuron.com
Industry/Sector Biotechnology
Market Cap ($M) 22
IMC Share Price $0.100
Day High $0.103
Day Low $0.100
Last Close $0.100
IMC Share Price Movement - ( No change )
Prices as at 16:40, 19 Apr 2024
+Security prices are delayed by at least 20 minutes and are indicative only.
Upsell Banner

IMC Related Research

Immuron Limited (IMC) Upcoming Dividends & Yields

There are no dividends for Immuron Limited (IMC). Please use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Immuron Limited (IMC) Recent ASX Announcements

Headline Annoucement date/time+ Price at announcement+ Current price+ Price 7D Avg Gain/Loss
Immuron to host Live Virtual Event 15 Apr 2024 10:34AM $0.105 $0.100 $0.110 fallen by 4.76%
Immuron Travelan sales continued strong growth 10 Apr 2024 9:00AM $0.110 $0.100 $0.110 fallen by 9.09%
Change in substantial holding 22 Mar 2024 8:24AM $0.099 $0.100 $0.110 risen by 1.01%
  • + Company announcements and prices are delayed by at least 20 minutes. Prices are indicative only.

See all ASX announcements from Immuron Limited (IMC) or use our ASX Announcements tool to search for announcements across all ASX-listed securities.

IMC Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2023A -$3.79 -$1.70 32.80% 0.00 0.00 0.00% 0.0%
2022A -$2.85 -$1.30 -63.80% 0.00 0.00 0.00% 0.0%
2021A -$7.62 -$3.50 107.80% 0.00 0.00 0.00% 0.0%

IMC Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2021 A 2022 A 2023 A 2021 A 2022 A 2023 A 2021 A 2022 A 2023 A
CSL (CSL) $131,744M -0.0712 0.1072 0.1864 39.8999 36.0370 30.3755 1.31% 1.23% 1.38%
Clinuvel Pharmaceuticals (CUV) $759M 0.4665 0.2049 0.1566 25.6345 21.2751 18.3949 0.33% 0.46% 0.53%
Immuron (IMC) $23M 0.3280 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Mesoblast (MSB) $856M -0.1037 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals (TLX) $4,144M -1.3767 0.0000 0.0000 99.3661 0.0000 0.0000 0.00% 0.00% 0.00%

IMC Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 1.16 0.00
Market 0.53 15.30 1.11 1.01
Sector 1.26 21.30 1.92 0.98

IMC Directors

Name Position Start Date
Dr Roger Aston Non-Executive Director 25 May 2012
Mr Daniel Pollock Non-Executive Director 11 Oct 2012
Mr Stephen Anastasiou Non-Executive Director 28 May 2013
Mr Ravi Savarirayan Non-Executive Director 7 Apr 2017
Mr Paul Brennan Non-Executive Director, Non-Executive Chairman 16 Mar 2022

Immuron Limited (IMC) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
12 Mar 2024 POLLOCK, Daniel Buy Direct Shares 200,000 $0.120 $24,000.000
12 Mar 2024 POLLOCK, Daniel Exercise Options 200,000 $0.120 $24,000.000
8 Mar 2024 POLLOCK, Daniel Sell Direct Shares 200,000 $0.157 $31,400.000

See all changes in directors' interest & trades for Immuron Limited (IMC) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

IMC Management

Name Position
Flavio Palumbo Chief Commercial Officer
Jerry Kanellos Chief Operating Officer
Steven Lydeamore Chief Executive Officer
Phillip Hains Chief Financial Officer,Company Secretary

IMC Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Immuron Limited (IMC). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
77,567,160 (34.05%) BNYMC Group

IMC Calendar of Events

Date Event
26 February 2025 Report (Interim)
26 September 2024 Report (Annual)
28 August 2024 Report (Prelim)

FAQs about Immuron Limited (IMC)

Immuron Limited's (IMC) current share price is $0.10. This constitutes a price movement of 9.09% when compared to the share price 7 days ago and is -31.03% below IMC's 12-month high of $0.15 per share. Prices are delayed by at least 20 minutes.

Relative to the previous close share price of $0.10, Immuron Limited's (IMC) current share price of $0.10 constitutes a movement of or 0%. Immuron Limited's (IMC) share price movement is -9.09% when compared to 7 days ago and is -31.03% below IMC's 52-week high of $0.15.

Immuron Limited's (IMC) 52-week high is $0.15 which was reached on 8 Mar 2024. Relative to this, IMC's current share price of $0.10 constitutes a -$0.05 or -31.03% drop since that high of $0.15 per IMC share.

Immuron Limited's (IMC) 52-week low is $0.07 which was reached on 4 Mar 2024. Relative to this, IMC's current share price of $0.10 constitutes a $0.03 or 51.52% gain since that low of $0.07 per IMC share.

Over the last 12 months, Immuron Limited (IMC) has a daily average trading volume of 429,947 IMC shares per day.

Immuron Limited (IMC) has a current dividend yield of n/a this year. Last year's dividend yield was 0%. The dividend yield for IMC is a ratio that tells you the percentage of Immuron Limited's (IMC) share price that it pays out in dividends each year.

Immuron Limited (IMC) will release its next Annual Report on 26 September 2024. Immuron Limited's (IMC) last annual report was released on 28 Sep 2023. Click here to view Immuron Limited's (IMC) last annual report.

Immuron Limited (IMC) is classified as Health Care. Other companies in this sector include CSL Limited (CSL), ResMed Inc. (RMD), Cochlear Limited (COH), and Fisher & Paykel Healthcare Corporation Limited (FPH).

The price-to-earnings (P/E) ratio for Immuron Limited (IMC) is 0. The price-to-earnings ratio, also known as P/E ratio, P/E, or PER, is the ratio of Immuron Limited's (IMC) share price to its earnings per IMC share.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.